| 摘要: | 骨質疏鬆症是一種僅次於冠狀動脈心臟病的疾病，晚年骨質疏鬆症的發生有60%源自於成長期骨骼質量巔峰的累積量不足。非晶型碳酸鈣 (amorphous calcium carbonate, ACC) 有更高的生物可利用率，在預防骨質流失、促進骨形成和骨骼強度方面都較具優勢；此外，鈣還參與肌肉功能的調節和脂質的代謝。本研究將3週齡雄性Wistar大鼠分成四組：控制組 (C)、低劑量組 (L，20.65 mg/kg body weight (BW) ACC)、中劑量組 (M，206.5 mg/kg BW ACC) 和高劑量組 (H，413 mg/kg BW ACC)，以管灌的方式介入，持續12週。結果顯示成長型大鼠補充ACC可顯著增加骨小樑厚度、血清成骨細胞代謝指標和骨質密度，並降低血清蝕骨細胞代謝指標；此外，還顯著減少了腎周脂肪組織重量和肝臟總膽固醇濃度。因此ACC可以透過增加成骨細胞的代謝和降低蝕骨細胞的代謝，進而增加骨小樑厚度和骨質密度，增進骨骼的成長，並可能具有改善體脂肪堆積的潛力。
Osteoporosis is a significant disease globally, second only to coronary artery heart disease. In the elderly, approximately 60% of osteoporosis cases stem from an insufficient accumulation of bone mass during the growth period. Amorphous calcium carbonate (ACC) has a higher bioavailability. ACC can prevent bone loss, promote bone formation, and enhance bone strength. In addition, calcium is also involved in the regulation of muscle function and lipid metabolism. 3-week-old male Wistar rats were divided into 4 groups: control group (C), low-dose group (L, 20.65 mg/kg body weight (BW) ACC), medium-dose group (M, 206.5 mg/kg BW ACC), and high-dose group (H, 413 mg/kg BW ACC), administered by gavage for 12 weeks. Results showed that ACC supplementation in growing rats increased trabecular bone thickness, serum bone formation biomarkers, bone mineral density (BMD), and decreased serum bone resorption biomarkers and liver total cholesterol. Moreover, we observed decreasing trends in perirenal white adipose tissue and serum free fatty acid. In conclusion, ACC supplementation improved osteoblasts' metabolism and reduced osteoclasts' metabolism. Therefore, increased trabecular bone thickness and BMD, and promoted bone growth. Otherwise, ACC may have the potential to improve body fat accumulation. |
